Publications by authors named "Michael Emig"

Claim this Profile
A
Author Correction: Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial.
Yago Nieto, Pinaki Banerjee, Indreshpal Kaur, Rafet Basar, Ye Li, Michael Emig

Nat Med· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial.
Yago Nieto, Pinaki Banerjee, Indreshpal Kaur, Rafet Basar, Ye Li, Michael Emig

Nat Med· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-Human Phase I Study of a CD16A Bispecific Innate Cell Engager, AFM24, Targeting EGFR-Expressing Solid Tumors.
Anthony El-Khoueiry, Omar Saavedra, Jacob Thomas, Claire Livings, Elena Garralda, Michael Emig

Clin Cancer Res· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase II Study of Acimtamig (AFM13) in Patients with CD30-Positive, Relapsed, or Refractory Peripheral T-cell Lymphomas.
Won Seog Kim, Jake Shortt, Pier Luigi Zinzani, Natalia Mikhailova, Dejan Radeski, Michael Emig

Clin Cancer Res· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor Response and Symptom Palliation from RAINBOW, a Phase III Trial of Ramucirumab Plus Paclitaxel in Previously Treated Advanced Gastric Cancer.
Stefano Cascinu, György Bodoky, Kei Muro, Eric Van Cutsem, Sang Cheul Oh, Michael Emig

Oncologist· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOW.
Kei Muro, Jae Yong Cho, Gyorgy Bodoky, Chanchal Goswami, Yee Chao, Michael Emig

J Gastroenterol Hepatol· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data.
Charles S Fuchs, Kei Muro, Jiri Tomasek, Eric Van Cutsem, Jae Yong Cho, Michael Emig

J Gastric Cancer· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab.
Charles S Fuchs, Josep Tabernero, Jiří Tomášek, Ian Chau, Bohuslav Melichar, Michael Emig

Br J Cancer· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer.
Kohei Shitara, Kei Muro, Yasuhiro Shimada, Shuichi Hironaka, Naotoshi Sugimoto, Michael Emig

Gastric Cancer· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.
Hansjochen Wilke, Kei Muro, Eric Van Cutsem, Sang-Cheul Oh, György Bodoky, Michael Emig

Lancet Oncol· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.
Robert Pirker, Jose R Pereira, Aleksandra Szczesna, Joachim von Pawel, Maciej Krzakowski, Michael Emig

Lancet· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Leukocytoclastic vasculitis and acute renal failure after influenza vaccination in an elderly patient with myelodysplastic syndrome.
Silke Ulm, Margit Hummel, Michael Emig, Manuel Barreto-Miranda, Walter Back

Onkologie· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Loss of p53 impedes the antileukemic response to BCR-ABL inhibition.
Hans-Guido Wendel, Elisa de Stanchina, Enriqué Cepero, Sagarika Ray, Michael Emig

Proc Natl Acad Sci U S A· May 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders.
Amy V Jones, Sebastian Kreil, Katerina Zoi, Katherine Waghorn, Claire Curtis, Michael Emig

Blood· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fractalkine-upregulated milk-fat globule EGF factor-8 protein in cultured rat microglia.
Fernando Leonardi-Essmann, Michael Emig, Yoshihisa Kitamura, Rainer Spanagel, Peter J Gebicke-Haerter

J Neuroimmunol· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adding weekly irinotecan to high-dose 5-fluorouracil and folinic acid (HD-5-FU/FA) after failure for first-line HD-5-FU/FA in advanced colorectal cancer--a phase II study.
Ralf Hofheinz, Gernot Hartung, Stefan Samel, Michael Emig, Lothar Pilz

Anticancer Drugs· November 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis